Being potentially effective and applicable, pretreatment serum level of sIL-2R in DLBCL patients deserves to be considered as another important tool for identifying those with poor prognosis, whereas serum IL-18 level should be studied in larger prospective studies. This evidence concerns the gene IL18 and diffuse large B-cell lymphoma.